Preclinical Assessment of the Safety of Drone Brood Homogenate and Validation of Its Pharmacological Effects

Despite extensive research, the study of metabolic syndrome and its integration with other pathological conditions remains highly relevant. The complex interplay of various pathogenic mechanisms necessitates the development of new diagnostic and therapeutic tools. Drone brood homogenate, a compound with a multifaceted chemical composition, shows considerable promise for contemporary research. Its broad safety profile and applicability across different age groups further highlight its potential as a research subject. This study focused on evaluating the pharmacological safety of drone brood homogenate, including its acute toxicity, effects on gastrointestinal functional and motor activity, local irritation of the gastric mucosa, and influence on gastric secretory function. All experiments were conducted using established classical methods. The specific pharmacological activity of drone brood homogenate was assessed in comparison to metformin in an experimental model of fructose-induced metabolic syndrome. Laboratory animals from the Vivarium of I. Horbachevsky Ternopil National Medical University was used, with all procedures meeting bioethical standards. Results demonstrated that lyophilized drone brood homogenate does not cause local irritation, gastric ulcers, or alterations in gastric secretory function or gastrointestinal motility, indicating its low toxicity and potential for safe long-term use. As expected, animals with induced metabolic syndrome exhibited significant increases in glucose, insulin, and HOMA index. Administration of drone brood homogenate produced a relatively favorable effect on these metabolic parameters. Therefore, drone brood homogenate represents a promising active pharmaceutical agent for correcting biochemical disturbances associated with metabolic syndrome.